BC Week In Review | Feb 1, 2017
Clinical News

CSL112: Ph IIb AEGIS-I data

CSL said the double-blind, placebo-controlled, international Phase IIb AEGIS-I trial in 1,258 acute MI patients showed that once-weekly 2 and 6 g doses of IV CSL112 for 4 weeks each met the co-primary endpoints of...
BC Week In Review | Nov 24, 2014
Clinical News

CSL112: Phase IIb started

CSL began the double-blind, placebo-controlled, dose-escalation, international Phase IIb AEGIS-I trial to evaluate 2 dose levels of once-weekly IV CSL112 for 4 weeks in 1,200 patients who experienced an AMI. CSL Ltd. (ASX:CSL), Melbourne, Australia...
BC Week In Review | Nov 25, 2013
Clinical News

CSL112: Phase IIa data

A double-blind, placebo-controlled, U.S. Phase IIa trial in 44 patients with stable atherothrombotic disease showed that single doses of 1.7, 3.4 and 6.8 g CSL112 were well tolerated with no clinically-significant elevations in AST or...
BioCentury | Nov 25, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €4 (21%) to €15 on Friday after EMA's CHMP issued a negative opinion recommending against approval of an MAA for Masican masitinib to treat gastrointestinal stromal tumors (GIST)...
BC Week In Review | Dec 3, 2012
Clinical News

CSL112: Phase I data

A double-blind, placebo-controlled, Australian Phase I trial in 36 healthy volunteers showed that CSL112 was well tolerated with no treatment-related adverse events reported. The most common adverse event reported was vessel puncture site hematoma, which...
BC Week In Review | Dec 3, 2012
Clinical News

CSL112: Phase I data

A double-blind, placebo-controlled, Australian Phase I trial in 57 healthy volunteers showed that single ascending-doses of 5-135 mg/kg CSL112 caused dose-proportional elevation from baseline in APOA1, pre-beta HDL, cholesterol efflux capacity, movement of free cholesterol...
Items per page:
1 - 6 of 6